b'MOQC Measures: Medical Oncology (Med Onc) and Gynecology Oncology (Gyn Onc)As of June 2019, our practices will now see measures launched in their QOPI accounts as Med Onc or as Gyn Onc tracks. Our gynecology oncology measures are the same, but for Round 2 2019, MOQCs revised medical oncology measures have been launched. If you did not have a chance to attend our August abstractor webinar, it is available on moqc.org under QOPI abstraction. QOPIModule& TrackMeasure#QOPIMeasureName MedOncGynOncCore 6ePain addressed appropriately by second office visit and during most recent office visits(defect-free measure, 6 and 6d)Core 13oc6Oral chemotherapy monitored on visit/contact following start of therapy (defect-free measure 13oc6a - 13oc6b) Core 13oc6aOral chemotherapy adherence assessed on visit/contact following start of therapyCore 13oc6bOral chemotherapy adherence addressed on visit/contact following start of therapy Core 14Signed patient consent for chemotherapyCore22bb* TobaccocessationcounselingadministeredorpatientreferredinpastyearSMT 28NK1-RA & olanzapine prescribed or administered with high-emetic risk chemotherapy SMT28a* NK1-RAorolanzapineadministeredwithlowormoderateemeticriskCycle1chemotherapy(lowerisbetter) (Top5measure)SMT 33Infertility risks discussed prior to chemotherapy with patients of reproductive ageEOL 38Pain addressed appropriately (assessed, quantified, & plan of care documented for moderate-to-severe pain)EOL 41Dyspnea addressed appropriately (defect-free measure, 39 and 40)EOL42* Hospiceenrollment EOL 43aPalliative care referral/services EOL 44Hospice enrollment within 3 days of death (lowerisbetter)EOL 45Hospice enrollment within 7 days of death (lowerisbetter) EOL47a* Hospiceenrollment,ordocumenteddiscussionEOL 47bPalliative care referral/services, or documented discussionEOL 48Chemotherapy administered within the last two weeks of life (lowerisbetter)BR 62a1PET, CT, or radionuclide bone scan ordered by practice within 60 days after diagnosis for Stage I, IIA orIIB breast cancer (lowerisbetter)(Top5measure) BR 62c1Serum tumor marker surveillance ordered by practice between 30365 days after diagnosis of breast cancerin patients who received treatment with curative intent(lowerisbetter)(Top5measure)PROS 113Bone density testing to monitor for bone loss within a year of starting ADT for treatment of prostate cancer GYNONC 90gOperative report with documentation of residual disease within 48 hours of cytoreduction for womenwith invasive ovarian, fallopian tube, or primary peritoneal cancerGYNONC 94Platin or taxane administered within 28 days following cytoreduction to women with invasive Stage I (grade 3),IC-IV ovarian, fallopian tube, or primary peritoneal cancerMOQC PM1Bone-modifying agent administered for breast cancer bone metastases & multiple myeloma MOQC PM2**Complete family history documented in patients with invasive cancer MOQC PM3GCSF administered to patients who received chemotherapy with non-curative intent (lowerisbetter) (Top5measure)MOQC GYNONC #1Days from debulking surgery to chemotherapy startMOQC GYNONC #2Patients with ovarian cancer referred for genetic testing/counseling* Med Onc Value-Based Reimbursement (VBR) Measure (highlighted in lavender)**QOPI Core Measure 10 chemotherapy intent documented before or within two weeks after administration will be abstracted from MOQC charts to support PM2Top 5 Measure = Choosing Wisely Measure http://www.choosingwisely.org/MOQC PM = Michigan Oncology Quality Consortium Pilot Measure or Test Measure with QOPI continued on next page4'